Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

15.38 +3.43 (+28.70%)
Streaming Delayed Price Updated: 9:44 AM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Silence Therapeutics to Participate in September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence (SLN) Q2 Revenue Drops 71% ↗
Via The Motley Fool
News headline image
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
The Analyst Landscape: 6 Takes On Silence Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 4 Ratings For Silence Therapeutics ↗
 
Via Benzinga
News headline image
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
From Silence Therapeutics plc
Via Business Wire
News headline image
These stocks are moving in today's pre-market session ↗
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Analyst Expectations For Silence Therapeutics's Future ↗
 
Via Benzinga
News headline image
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Silence Therapeutics plc
Via Business Wire
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15 ↗
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks That May Explode In Q4 ↗
 
Via Benzinga
News headline image
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst ↗
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges. 
Via Benzinga
News headline image
Top 3 Health Care Stocks You'll Regret Missing In Q4 ↗
 
Via Benzinga
News headline image
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.